SpeeDx Increase European Distribution Network
SpeeDx have announced signing two new distribution partners, creating comprehensive access for customers to market-leading SpeeDx Resistance Plus ® and Plex PCR ® tests across Europe. AB ANALITICA will distribute throughout Italy and Immuno Diagnostic Oy will cover Finland.
“Our new distribution partners have strong sales presence in their regions and close working relationships with the key customers that are interested in our solutions,” says Colin Denver, SpeeDx CEO. “Antibiotic resistance in sexually transmitted diseases is a top concern for authorities and testing bodies across Europe, and now more laboratories can access our ResistancePlus tests for Mycoplasma genitalium and gonorrhoea to help address the real need for Resistance Guided Therapy.”
The SpeeDx Resistance Plus portfolio includes Resistance Plus GC* (CE-IVD) - the first commercially available test that combines Neisseria gonorrhoeae (GC) detection with markers for ciprofloxacin susceptibility. Resistance Plus GC enables stewardship of last-line antibiotic treatments by directing therapy towards ciprofloxacin when appropriate. Ciprofloxacin is a simple oral antibiotic, and surveillance data indicates it is still effective for up to 70% of gonorrhoea infections.1-4 The market-leading Resistance Plus MG assay from SpeeDx simultaneously detects Mycoplasma genitalium and genetic markers for azithromycin resistance, with demonstrated clinical outcomes of increased patient cure rate up to 92% compared with 40% cure rates when using MG-detection-only testing.5 SpeeDx also plans to release a new Resistance Plus MG test for resistance markers linked to second-line antibiotic treatment failure.
The SpeeDx portfolio also includes Plex PCR VHS - a multiplex test for herpes simplex virus (1 and 2), varicella zoster and Treponema pallidum (syphilis). Further tests in the Plex PCR portfolio include plans for a comprehensive multiplex panel for respiratory virus testing as well as a respiratory bacterial infection testing solution.
*available where CE-mark is accepted, not available in the U.S. or A.U.
1. Harris SR et al. Lancet Infect Dis Published online May 15th 2018.
2. Lahra MM et al. Australian Gonococcal Surveillance Programme annual report, 2015
3. Heffernan H et al. Antimicrobial resistance and molecular epidemiology of gonococci in NZ, 2014-5
4. Kirkcaldy RD et al. MMWR Surveillance Summaries July 15, 2016 / 65(7);1–19
5. Read TRH. et al CID June 5 2018 doi.org/10.1093/cid/ciy477.
Founded in 2009, SpeeDx is an Australian-based private company with
offices in London and the US, and distributors across Europe. SpeeDx
specializes in molecular diagnostic solutions that go beyond simple
detection to offer comprehensive information for improved patient
management. Innovative real-time polymerase chain reaction (qPCR)
technology has driven market-leading multiplex detection and priming
strategies. SpeeDx has a portfolio of CE-IVD kits for detection of
infectious disease pathogens, sexually transmitted infection (STI), and
antimicrobial resistance markers and is currently conducting clinical
trials for FDA clearance in 2019. SpeeDx Resistance
tests enable Resistance Guided Therapy, improving patient outcomes by
empowering practitioners to make informed clinical decisions.
For more information about SpeeDx please see: http://plexpcr.com
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-ANDERSEN-TAX23.8.2019 14:18:12 CEST | Pressemeddelelse
Andersen Global debuterer i Colombia
KERING23.8.2019 09:49:11 CEST | Press release
32 Leading Global Fashion and Textile Companies Make Commitments on Climate, Biodiversity and Oceans
BITFLYER23.8.2019 07:02:02 CEST | Press release
Ethereum (ETH) Now Available on bitFlyer Buy/Sell
STALICLA23.8.2019 02:02:11 CEST | Press release
STALICLA Announces Completion of pre-IND Meeting With FDA on STP1 for Subgroup of Patients With Autism Spectrum Disorder (ASD)
NV-RIMINI-STREET,-INC.23.8.2019 00:02:07 CEST | Press release
San Fang Chemical Switches to Rimini Street Support for its Oracle EBS and Oracle Database Software
GRAVITY-INTERACTIVE22.8.2019 17:48:03 CEST | Press release
Gravity Unveils its Future Plans During Gamescom 2019
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom